Taiwan Bio Therapeutics Inc

Capital Structure and Liquidity The company has a debt-to-equity ratio of 0.76, indicating moderate leverage relative to equity. Total liabilities of TWD 625.12 million exceed total equity of TWD 729.60 million, but the debt-to-equity ratio remains below 1.0, suggesting manageable leverage. However, operating cash flow is negative at TWD -212.31 million, and capital expenditures are TWD -32.11 million, indicating ongoing cash outflows. The liquidity risk is assessed as medium, with a key flag noting that net cash is negative after subtracting total debt. ### Profitability and Returns The company’s revenue is TWD 50.43 million, but no profitability metrics such as net income or EBITDA are provided in the input data. Without these, it is not possible to assess profitability relative to industry_config preferred metrics or cohort medians. The absence of positive operating cash flow further limits the ability to evaluate returns on invested capital or margins. ### Segments and Geographic Exposure The company operates primarily in the Taiwan market, with no disclosed international revenue. Its business is divided into product development (stem cell drugs) and CDMO services. No segment-specific revenue figures are provided, so it is not possible to assess revenue concentration or geographic diversification. ### Growth Trajectory No growth trajectory data is available in the input, as no revenue history or outlook figures are provided. The company’s current FY and next FY direction cannot be assessed without numeric deltas or forward-looking guidance. ### Risk Factors and Dilution Potential The company faces medium liquidity risk due to negative operating cash flow and a negative net cash position. Dilution risk is assessed as low, with no dilution potential reported in the input data. No adjustments are applied to the valuation in the custom_valuations section, suggesting no material dilution events have occurred. ### Recent Events No recent events such as filings, transcripts, or material disclosures are provided in the input data.